Treatment With AX200 for Acute Ischemic Stroke

Completed

Phase 2 Results

Summary of Purpose

The AXIS study is a randomized, double-blind, placebo-controlled, dose-escalating phase IIa trial to investigate treatment with AX200 (granulocyte-colony stimulating factor; G-CSF) for acute ischemic stroke. The primary objective of the present phase IIa study is to assess the safety and tolerability of AX200 compared to placebo in subjects suffering from acute stroke. The secondary objective is to assess the...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 23 July 2007.

1 Dec 2004 18 Aug 2005 Unavailable 1 Mar 2007 1 Jul 2007 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Conditions

Sponsors

Trial Design

  • Allocation: Randomized
  • Masking: Double-Blind
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Single Group Assignment

Contacts

  • Dr. Rico Laage -Project Leader AXIS Trial- SYGNIS Bioscience GmbH & Co KG Im Neuenheimer Feld 515 69120 Heidelberg, Germany Phone +49(0)6221 454724 Fax +49(0)6221 454700

    Rico.Laage@sygnis.de